Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 13;17(12):1982.
doi: 10.3390/cancers17121982.

What Is the Survivorship of Megaprosthetic Reconstruction Following the Resection of Renal Cell Carcinoma Long Bone Metastases and What Are the Potential Risk Factors for a Prosthetic Complication?

Sebastian Bockholt  1 , Kristian Nikolaus Schneider  1 , Georg Gosheger  1 , Maria Anna Smolle  2 , Niklas Deventer  1 , Dimosthenis Andreou  1   3 , Christoph Theil  1
Affiliations

What Is the Survivorship of Megaprosthetic Reconstruction Following the Resection of Renal Cell Carcinoma Long Bone Metastases and What Are the Potential Risk Factors for a Prosthetic Complication?

Sebastian Bockholt et al. Cancers (Basel). .

Abstract

Background: Long bone metastases are common in patients with metastatic renal cell carcinoma (RCC). One potential surgical treatment option is resection and megaprosthetic reconstruction. However, implant complications and survival are poorly understood. This study analyzes patient and implant survival as well as associated risk factors. Methods: This is a retrospective study from a single academic center, analyzing 86 patients that underwent resection and megaprosthetic reconstruction performed between 1993 and 2017. The most common location of megaprosthetic reconstruction was the proximal femur (PFR) in 38% (33 of 86) of patients. We calculated overall patient survival and associated risk factors using the Kaplan-Meier method and implant survivorship using a competing risk analysis. Results: A total of 73% (63/86) of patients died of their disease after a median of 19 (IQR 9-37) months following surgery, and a median of 71 (IQR 31-132) months after the initial diagnosis of RCC. The overall survival probability was 29% (95% CI 18-40%) five years after surgery. The five-year risk of revision surgery (within a competing risk framework) was 18% (95% CI 11-28). A total of 8% (7 of 86) of patients underwent an exchange of the implant itself. Patients with total bone replacements had a higher revision risk (SHR 19.46 (95% CI 6.9-54.9), p < 0.01). Furthermore, the revision risk was higher with increasing reconstruction length per mm (SHR 1.01 (95% CI 1.01-1.02), p = 0.03) and prolonged surgical time per minute (SHR: 1.01 (95% CI 1.0-1.02), p < 0.01). Local postoperative radiation treatment (RTX) was associated with an increased risk for revisions (SHR 2.59 (95% CI 0.96-6.95), p = 0.06). Conclusions: Modular megaprostheses demonstrated a fairly low risk of implant revision although postoperative radiation therapy and total bone replacements are associated with an increased risk.

Keywords: bone metastasis; megaprostheses; megaprosthesis; renal cell caricnoma.

PubMed Disclaimer

Conflict of interest statement

Three of the authors (M.A.S.; C.T.; D.A.) declare the reception of travel grants or honoraria for presentations by implantcast GmbH, Germany; Alphamed Fischer, Austria; Implantect, Austria; PharamMar, Austria; Rimasys GmbH, Germany; Nuvasive GmbH, Germany. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 2
Figure 2
Cumulative incidence function of any implant-related complications over time.
Figure 1
Figure 1
Overall patient survivorship curve in months.
See this image and copyright information in PMC

References

    1. Flanigan R.C., Campbell S.C., Clark J.I., Picken M.M. Metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 2003;4:385–390. doi: 10.1007/s11864-003-0039-2. - DOI - PubMed
    1. Bianchi M., Sun M., Jeldres C., Shariat S.F., Trinh Q.D., Briganti A., Tian Z., Schmitges J., Graefen M., Perrotte P., et al. Distribution of metastatic sites in renal cell carcinoma: A population-based analysis. Ann. Oncol. 2012;23:973–980. doi: 10.1093/annonc/mdr362. - DOI - PubMed
    1. Santini D., Procopio G., Porta C., Ibrahim T., Barni S., Mazzara C., Fontana A., Berruti A., Berardi R., Vincenzi B., et al. Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastasis survey. PLoS ONE. 2013;8:e83026. doi: 10.1371/journal.pone.0083026. - DOI - PMC - PubMed
    1. Ratasvuori M., Wedin R., Hansen B.H., Keller J., Trovik C., Zaikova O., Bergh P., Kalen A., Laitinen M. Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. J. Surg. Oncol. 2014;110:360–365. doi: 10.1002/jso.23654. - DOI - PubMed
    1. Higuchi T., Yamamoto N., Hayashi K., Takeuchi A., Abe K., Taniguchi Y., Kato S., Murakami H., Tsuchiya H. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Jt. J. 2018;100-B:1241–1248. doi: 10.1302/0301-620X.100B9.BJJ-2017-1163.R3. - DOI - PubMed